Coya TherapeuticsCOYA
13F holders, Q1 2024 (March 31)19holders
1famous investor
$9.92avg. 13F price*
At the end of Q1 2024, 19 institutions reported holding Coya Therapeutics Inc. (COYA) in their 13F filings. The largest holders were Greenlight Capital (DME Capital Management) ($12.6M), Vanguard Group Inc. ($8.4M) and AIGH Capital Management LLC ($6.4M). One famous investor held it David Einhorn (0.6% of Greenlight Capital (DME Capital Management)'s portfolio).
- Company
- Coya Therapeutics Inc.
- CUSIP
- 22407B108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $1.7M |
| Exits | 4 | $840K |
Ownership 19 holders
| Greenlight Capital (DME Capital Management) | 0.58% | No change | 1,274,026 | $12.6M |
| Vanguard Group Inc. | 0.00% | Add +772.3% | 847,490 | $8.4M |
| AIGH Capital Management LLC | 3.11% | Reduce -37.1% | 649,427 | $6.4M |
| Geode Capital Management, LLC | 0.00% | Add +36.3% | 125,996 | $1.3M |
| Raymond James & Associates | 0.00% | New | 110,095 | $1.1M |
| CM Management, LLC | 0.83% | No change | 100,000 | $992K |
| BlackRock Inc. | 0.00% | Add +148.0% | 53,997 | $536K |
| State Street Corp. | 0.00% | New | 46,200 | $458K |
| Prelude Capital Management, LLC | 0.02% | No change | 35,770 | $355K |
| Royal Bank of Canada | 0.00% | Add +14951.2% | 31,457 | $312K |
| Northern Trust Corp. | 0.00% | Add +71.2% | 25,467 | $253K |
| Jane Street Group, LLC | 0.00% | New | 20,078 | $199K |
| Mirador Capital Partners LP | 0.03% | Reduce -4.0% | 15,481 | $154K |
| Bank of America Corp. | 0.00% | Add +16150.0% | 1,625 | $16K |
| UBS Group AG | 0.00% | Reduce -75.8% | 600 | $6K |
| Morgan Stanley | 0.00% | Add +6.4% | 532 | $5K |
| JPMorgan Chase & Co. | 0.00% | Add +715.4% | 530 | $5K |
| Tucker Asset Management LLC | 0.00% | No change | 200 | $2K |
| Wells Fargo & Company | 0.00% | Add +53.9% | 100 | $992 |
"% of holder's portfolio" is COYA's weight in each manager's 13F, not the share of Coya Therapeutics Inc. the manager owns.